Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
42.9M
-
Number of holders
-
139
-
Total 13F shares, excl. options
-
46.8M
-
Shares change
-
+7.74M
-
Total reported value, excl. options
-
$1.84B
-
Value change
-
+$358M
-
Put/Call ratio
-
0.97
-
Number of buys
-
93
-
Number of sells
-
-46
-
Price
-
$39.35
Significant Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value (DNTH) as of Q3 2025
160 filings reported holding DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value as of Q3 2025.
Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value (DNTH) has 139 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.8M shares
.
Largest 10 shareholders include FMR LLC (5.97M shares), Fairmount Funds Management LLC (3.31M shares), Avidity Partners Management LP (3.2M shares), RA CAPITAL MANAGEMENT, L.P. (2.87M shares), WELLINGTON MANAGEMENT GROUP LLP (2.58M shares), Octagon Capital Advisors LP (2.42M shares), Point72 Asset Management, L.P. (2.04M shares), TCG Crossover Management, LLC (1.68M shares), VANGUARD GROUP INC (1.64M shares), and BlackRock, Inc. (1.34M shares).
This table shows the top 139 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.